Won Park

4.6k citations

97 papers · 3.3k · 2 hit papers · h-index 25

Impact in

Immunology top 1%
- Biosimilars and Bioanalytical Methods
Rheumatology top 0.5%
- Rheumatoid Arthritis Research and Therapies
- Spondyloarthritis Studies and Treatments

Papers in

Rheumatology 43
- Rheumatoid Arthritis Research and Therapies 23
- Spondyloarthritis Studies and Treatments 13
- Systemic Lupus Erythematosus Research 6
Immunology 18
- Biosimilars and Bioanalytical Methods 13

Co-authors: Dae‐Hyun Yoo (22 shared papers)Pedro C. Miranda (4 shared papers)Sang Joon Lee (6 shared papers)Mie Jin Lim (27 shared papers)Sergio Gutiérrez‐Ureña (3 shared papers)Paweł Hrycaj (3 shared papers)Volodymyr Kovalenko (3 shared papers)Seong‐Ryul Kwon (33 shared papers)
Journals: Journal of Korean Medical Science (11 papers)Annals of the Rheumatic Diseases (8 papers)The Journal of Rheumatology (3 papers)Modern Rheumatology (3 papers)Cancer Research and Treatment (2 papers)
Partner nations: South Korea United States Mexico

In The Last Decade

Won Park

92 papers receiving 3.2k citations

Won Park's Hit Papers

align trajectories log scale

A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study 2013 · 463 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2013 Annals of the Rheumatic Diseases
2013 Annals of the Rheumatic Diseases

Peers

Countries citing papers authored by Won Park

Since Specialization

Citations

This map shows the geographic impact of Won Park's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Won Park with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Won Park more than expected).

Fields of papers citing papers by Won Park

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Won Park. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Won Park. The network helps show where Won Park may publish in the future.

Co-authors

The 25 scholars most cited alongside Won Park, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Won Park Line = papers co-authored together Won Park links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 97 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study Annals of the Rheumatic Diseases ·Dae‐Hyun Yoo, Paweł Hrycaj, Pedro C. Miranda, Edgar Ramiterre, Mariusz Piotrowski, S. Shevchuk, Volodymyr Kovalenko, Nenad Prodanović, Mauricio Abello-Banfi, Sergio Gutiérrez‐Ureña, Luis Morales-Olazabal, Michael Tee, Renato Jimenez, Omid Zamani, Sang Joon Lee, HoUng Kim, Won Park, Ulf Müller‐Ladner Hit paper breakdown →	2013	504
2	A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study Annals of the Rheumatic Diseases ·Won Park, Paweł Hrycaj, Sławomir Jeka, Volodymyr Kovalenko, Grygorii Lysenko, Pedro C. Miranda, Helēna Mikažāne, Sergio Gutiérrez‐Ureña, Mie Jin Lim, Yeon-Ah Lee, Sang Joon Lee, HoUng Kim, Dae‐Hyun Yoo, Jürgen Braun Hit paper breakdown →	2013	463
3	Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate‐naive patients with active rheumatoid arthritis: Twenty‐four–week results of a phase III, multicenter, randomized, double‐blind, placebo‐controlled study of golimumab before methotrexate as first‐line therapy for early‐onset rheumatoid arthritis Arthritis & Rheumatism ·Paul Emery, Roy Fleischmann, Larry W. Moreland, Elizabeth C. Hsia, Ingrid Strusberg, Patrick Durez, Peter Nash, Eric Amante, Melvin Churchill, Won Park, Bernardo A. Pons‐Estel, Mittie K. Doyle, Sudha Visvanathan, Weichun Xu, Mahboob U. Rahman	2009	349
4	Efficacy and Safety of CE-224,535, an Antagonist of P2X₇Receptor, in Treatment of Patients with Rheumatoid Arthritis Inadequately Controlled by Methotrexate The Journal of Rheumatology ·Thomas Stock, Bradley J. Bloom, Nathan Wei, Saliha Ishaq, Won Park, Xin Wang, Pankaj Gupta, Charles A. Mebus	2012	216
5	Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study Annals of the Rheumatic Diseases ·Dae‐Hyun Yoo, Nenad Prodanović, Janusz Jaworski, Pedro C. Miranda, Edgar Ramiterre, A Lanzon, Asta Baranauskaitė, Piotr Wiland, Carlos Abud‐Mendoza, Boycho Oparanov, Svitlana Smiyan, HoUng Kim, Sang Joon Lee, Suyeon Kim, Won Park	2016	210
6	Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study Annals of the Rheumatic Diseases ·Won Park, Dae‐Hyun Yoo, Pedro C. Miranda, Marek Brzosko, Piotr Wiland, Sergio Gutiérrez‐Ureña, Helēna Mikažāne, Yeon-Ah Lee, Svitlana Smiyan, Mie Jin Lim, Vladimir Kadinov, Carlos Abud‐Mendoza, HoUng Kim, Sang Joon Lee, Yunju Bae, Suyeon Kim, Jürgen Braun	2016	176
7	A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study Arthritis Research & Therapy ·Dae‐Hyun Yoo, Artur Racewicz, Jan Brzezicki, Roman Yatsyshyn, E. Tobias Arteaga, Asta Baranauskaitė, Carlos Abud‐Mendoza, Sandra Navarra, Vladimir Kadinov, Irmgadt Goecke Sariego, Seung Suh Hong, Sungyoung Lee, Won Park	2016	140
8	Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study Arthritis Research & Therapy ·Won Park, Dae‐Hyun Yoo, Janusz Jaworski, Jan Brzezicki, A. Gnylorybov, Vladimir Kadinov, Irmgadt Goecke Sariego, Carlos Abud‐Mendoza, William J. Otero Escalante, Seong Wook Kang, Daina Andersone, Francisco J. Blanco, Seung Suh Hong, Sun Hee Lee, Jürgen Braun	2016	111
9	Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy Rheumatology International ·Seong‐Ryul Kwon, Mie-Jin Lim, Chang‐Hee Suh, Shin‐Goo Park, Yeon-Sik Hong, Bo‐Young Yoon, Hyoun‐Ah Kim, Hyojin Choi, Won Park	2011	91
10	IgG antibodies to type II collagen reflect inflammatory activity in patients with rheumatoid arthritis. PubMed ·Wan‐Uk Kim, Wan‐Hee Yoo, Won Park, Younhee Kang, S I Kim, J.-H. Park, S S Lee, Y S Joo, Jun‐Ki Min, Yujie Hong, S H Lee, S H Park, C S Cho, H Y Kim	2000	56
11	Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial Modern Rheumatology ·Tsutomu Takeuchi, Yoshiya Tanaka, Hisashi Yamanaka, Kanzo Amano, Ryuji Nagamine, Won Park, Kazuko Shiozawa, Michishi Tsukano, James Cheng‐Chung Wei, Jing Shao, Osamu Togo, Hideki Mashimo	2015	52
12	Shift toward T helper 1 cytokines by type II collagen-reactive T cells in patients with rheumatoid arthritis Arthritis & Rheumatism ·Sung Hwan Park, Do‐June Min, Mi‐La Cho, Wan‐Uk Kim, Jeehee Youn, Won Park, Chul‐Soo Cho, Ho‐Youn Kim	2001	49
13	Comparison of the pharmacokinetics and safety of three formulations of infliximab (CT-P13, EU-approved reference infliximab and the US-licensed reference infliximab) in healthy subjects: a randomized, double-blind, three-arm, parallel-group, single-dose, Phase I study Expert Review of Clinical Immunology ·Won Park, Sang Joon Lee, Jihye Yun, Dae‐Hyun Yoo	2015	46
14	Digital Thermography of the Fingers and Toes in Raynaud's Phenomenon Journal of Korean Medical Science ·Mie Jin Lim, Seong‐Ryul Kwon, Kyong‐Hee Jung, Kowoon Joo, Shin‐Goo Park, Won Park	2014	42
15	Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis BioDrugs ·Won Park, Chang‐Hee Suh, Seung Cheol Shim, Francisco Fidencio Cons Molina, Sławomir Jeka, Francisco G. Medina-Rodriguez, Paweł Hrycaj, Piotr Wiland, Eun Young Lee, P. А. Shesternya, Volodymyr Kovalenko, L. Myasoutova, Marina Stanislav, S. Radominski, Mie Jin Lim, Jung‐Yoon Choe, Sang Joon Lee, Sungyoung Lee, Sung‐Hwan Kim, Dae‐Hyun Yoo	2017	37
16	Interleukin-18 as an efficient marker for remission and follow-up in patients with inactive adult-onset Still’s disease Scandinavian Journal of Rheumatology ·Jung Kh, Kim Jj, JS Lee, Won Park, (unknown), J-B Jun, DH Yoo	2013	36
17	Efficacy and Safety of Subcutaneous Golimumab in Methotrexate‐Naive Patients With Rheumatoid Arthritis: Five‐Year Results of a Randomized Clinical Trial Arthritis Care & Research ·Paul Emery, Roy Fleischmann, Ingrid Strusberg, Patrick Durez, Peter Nash, Eric Amante, Melvin Churchill, Won Park, Bernardo A. Pons‐Estel, Chenglong Han, Timothy Gathany, Stephen Xu, Yiying Zhou, Jocelyn H. Leu, Elizabeth C. Hsia	2015	35
18	Golimumab, a Human Anti–Tumor Necrosis Factor Monoclonal Antibody, Injected Subcutaneously Every 4 Weeks in Patients With Active Rheumatoid Arthritis Who Had Never Taken Methotrexate: 1‐Year and 2‐Year Clinical, Radiologic, and Physical Function Findings of a Phase III, Multicenter, Randomized, Double‐Blind, Placebo‐Controlled Study Arthritis Care & Research ·Paul Emery, Roy Fleischmann, Mittie K. Doyle, Ingrid Strusberg, Patrick Durez, Peter Nash, Eric Amante, Melvin Churchill, Won Park, Bernardo A. Pons‐Estel, Weichun Xu, Stephen Xu, Wu Zhong, Elizabeth C. Hsia	2013	35
19	A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study Annals of the Rheumatic Diseases ·Sang‐Cheol Bae, Jinseok Kim, Jung‐Yoon Choe, Won Park, Sang‐Heon Lee, Yong‐Beom Park, Seung Cheol Shim, Shin‐Seok Lee, Yoon‐Kyoung Sung, Chan‐Bum Choi, So-Ra Lee, HanYu Park, Yongho Ahn	2016	33
20	Monthly Oral Ibandronate Reduces Bone Loss in Korean Women With Rheumatoid Arthritis and Osteopenia Receiving Long-term Glucocorticoids: A 48-week Double-blinded Randomized Placebo-controlled Investigator-initiated Trial Clinical Therapeutics ·Kichul Shin, Sung‐Hwan Park, Won Park, Han Joo Baek, Yun Jong Lee, Seong Wook Kang, Jung‐Yoon Choe, Wan‐Hee Yoo, Yong‐Beom Park, Jung Soo Song, Seung‐Geun Lee, Bin Yoo, Dae‐Hyun Yoo, Yeong Wook Song	2017	29

About Won Park

Won Park is a scholar working on Rheumatology, Immunology, Pathology and Forensic Medicine, Hematology and Pulmonary and Respiratory Medicine, having authored 97 papers that have together received 3.3k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (23 papers), Biosimilars and Bioanalytical Methods (13 papers), Spondyloarthritis Studies and Treatments (13 papers), Autoimmune and Inflammatory Disorders Research (8 papers), Vasculitis and related conditions (6 papers), Gout, Hyperuricemia, Uric Acid (6 papers), Systemic Lupus Erythematosus Research (6 papers) and Bone and Joint Diseases (6 papers). The work is most often cited by research in Immunology (1.8k citations), Rheumatology (1.1k citations), Physiology (162 citations), Hematology (264 citations) and Pediatrics, Perinatology and Child Health (321 citations). Won Park has collaborated with scholars based in South Korea, United States and Mexico. Frequent co-authors include Dae‐Hyun Yoo, Pedro C. Miranda, Sang Joon Lee, Mie Jin Lim, Sergio Gutiérrez‐Ureña, Paweł Hrycaj, Volodymyr Kovalenko, Seong‐Ryul Kwon, HoUng Kim and Jürgen Braun. Their work appears in journals such as Journal of Korean Medical Science, Annals of the Rheumatic Diseases, The Journal of Rheumatology, Modern Rheumatology and Cancer Research and Treatment.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Won Park

Impact in

Papers in i

In The Last Decade

Won Park

Won Park's Hit Papers

Peers

Countries citing papers authored by Won Park

Fields of papers citing papers by Won Park

All Works

About Won Park

Explore authors with similar magnitude of impact

Papers in